Comment

  • 6 July 2017

    Merck’s Keytruda stumbles in multiple myeloma

    On 5 July, Merck & Co. announced that the FDA had placed clinical holds on three combination studies of its programmed cell death protein 1 (PD-1) inhibitor, Keytruda (pembrolizumab), in...

  • 27 June 2017

    EHA 2017: Novartis is Leading the CAR-T Cell Race

    On June 24th, at the 2017 European Hematology Association (EHA) annual meeting in Madrid, Spain, an updated interim analysis from Novartis’ ELIANA trial was presented. ELIANA is the first global...

Go Top